Place of sulfonylureas in the management of type 2 diabetes mellitus in South Asia: A consensus statement
Open accessThe DOI matches its Crossref record; 26 of the 26 references it cites were found in a registry or an index.
Abstract
Since their introduction in clinical practice in the 1950's, Sulfonylureas (SUs) have remained the main-stay of pharmacotherapy in the management of type 2 diabetes. Despite their well-established benefits, their place in therapy is inappropriately being overshadowed by newer therapies. Many of the clinical issues associated with the use of SUs are agent-specific, and do not pertain to the class as such. Modern SUs (glimepiride, gliclazide MR) are backed by a large body of evidence, experience, and most importantly, outcome data, which supports their role in managing patients with diabetes. Person-centred care, i.e., careful choice of SU, appropriate dosage, timing of administration, and adequate patient counseling, will ensure that deserving patients are not deprived of the advantages of this well-established class of anti-diabetic agents. Considering their efficacy, safety, pleiotropic benefits, and low cost of therapy, SUs should be considered as recommended therapy for the treatment of diabetes in South Asia. This initiative by SAFES aims to encourage rational, safe and smart prescription of SUs, and includes appropriate medication counseling.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Osterberg, L., & Blaschke, T. (2005) · New England Journal of Medicine · doi:10.1056/nejmra050100 · Cited by 7,974
10-year follow-up of intensive glucose control in type 2 diabetes
Holman, R. R., Paul, S. K., Bethel, M. A., Matthews, D. R., & Neil, H. A. W. (2008) · New England Journal of Medicine · doi:10.1056/nejmoa0806470 · Cited by 7,751 · cited 2×
“[26] This benefit persisted for up to 10 years in patients who had attained better glycaemic control.[60] Similar results were observed from 15 well designed long term (≥72‐weeks) RCTs, including ADOPT, ADVANCE[52] and ADVANCE‐ON,[61] where treatment with SUs was not found to be associated with an increase in CVD risk…”
Intensive blood glucose control and vascular outcomes in patients with type 2 diabetes
(2008) · New England Journal of Medicine · doi:10.1056/nejmoa0802987 · Cited by 7,397
Inzucchi, S. E., Bergenstal, R. M., Buse, J. B., Diamant, M., Ferrannini, E., Nauck, M., Peters, A. L., Tsapas, A., Wender, R., & Matthews, D. R. (2012) · Diabetologia · doi:10.1007/s00125-012-2534-0 · Cited by 3,919
Inzucchi, S. E., Bergenstal, R. M., Buse, J. B., Diamant, M., Ferrannini, E., Nauck, M., Peters, A. L., Tsapas, A., Wender, R., & Matthews, D. R. (2015) · Diabetes Care · doi:10.2337/dc14-2441 · Cited by 3,066
Glycemic durability of rosiglitazone, metformin, or glyburide monotherapy
Kahn, S. E., Haffner, S. M., Heise, M. A., Herman, W. H., Holman, R. R., Jones, N. P., Kravitz, B. G., Lachin, J. M., O'Neill, M. C., Zinman, B., et al. (2006) · New England Journal of Medicine · doi:10.1056/nejmoa066224 · Cited by 2,962
Pancreatic β Cell Dedifferentiation as a Mechanism of Diabetic β Cell Failure
Talchai, C., Xuan, S., Lin, H. V., Sussel, L., & Accili, D. (2012) · Cell · doi:10.1016/j.cell.2012.07.029 · Cited by 1,415
Cloning of the β Cell High-Affinity Sulfonylurea Receptor: a Regulator of Insulin Secretion
Aguilar-Bryan, L., Nichols, C. G., Wechsler, S. W., Clement, J. P., Boyd, A. E., González, G., Herrera-Sosa, H., Nguy, K., Bryan, J., & Nelson, D. A. (1995) · Science · doi:10.1126/science.7716547 · Cited by 1,315
A comparison of glyburide and insulin in women with gestational diabetes mellitus
Langer, O., Conway, D. L., Berkus, M. D., Xenakis, E. M.-J., & Gonzales, O. (2000) · New England Journal of Medicine · doi:10.1056/nejm200010193431601 · Cited by 924 · cited 1×
“[145‐147] Studies using a single‐cotyledon placental model have found minimal trans‐placental transfer of glibenclamide; an observation that paved the way for further research on its role in the management of gestational diabetes mellitus.[148,149] However, contradicting results from other studies, together with lack…”
Follow-up of glycemic control and cardiovascular outcomes in type 2 diabetes
Hayward, R. A., Reaven, P. D., Wiitala, W. L., Bahn, G. D., Reda, D. J., Ge, L., McCarren, M., Duckworth, W. C., & Emanuele, N. V. (2015) · New England Journal of Medicine · doi:10.1056/nejmoa1414266 · Cited by 668 · cited 2×
“This data provides evidence that a current multidrug glycemic treatment regimen (which includes glimepiride) can be associated with a significant reduction in major macrovascular events even among older patients who have had diabetes for many years.[62] The major outcomes of treatment with SUs in landmark trials have…”
Cited by
Volgman, A. S., Palaniappan, L. S., Aggarwal, N. T., Gupta, M., Khandelwal, A., Krishnan, A. V., Lichtman, J. H., Mehta, L. S., Patel, H. N., Shah, K. S., et al. (2018) · Circulation · doi:10.1161/cir.0000000000000580 · Cited by 552
Kalra, S., Bahendeka, S., Sahay, R., Ghosh, S., Md, F., Orabi, A., Ramaiya, K., Al Shammari, S., Shrestha, D., Shaikh, K., et al. (2018) · Indian Journal of Endocrinology and Metabolism · doi:10.4103/ijem.ijem_556_17 · Cited by 101
Self-citationHossain, M. A., & Pervin, R. (2018) · Nutritional and Therapeutic Interventions for Diabetes and Metabolic Syndrome · doi:10.1016/b978-0-12-812019-4.00034-9 · Cited by 47
Metadata
- Authors
- Kalra, S., Aamir, A., Raza, A., Das, A., Azad Khan, A., Shrestha, D., Qureshi, M. F., Fariduddin, M., Pathan, M. F., Jawad, F., Bhattarai, J., Tandon, N., Somasundaram, N., Katulanda, P., Sahay, R., Dhungel, S., Bajaj, S., Chowdhury, S., Ghosh, S., Madhu, S., Ahmed, T., & Bulughapitiya, U.
- Venue
- Indian Journal of Endocrinology and Metabolism
- Publisher
- Medknow
- Published
- 2015
- Volume
- 19
- Issue
- 5
- Pages
- 577
- ISSN
- 2230-8210 (ISSN-L)
- OpenAlex
- W1871508201
- Cited by
- 111
- References
- 26
- FWCI
- 8.61
- Type
- journal article
- Language
- en
- Open access
- diamond
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Place of sulfonylureas in the management of type 2 diabetes mellitus in South Asia: A consensus statement. https://app.cochat.ai/papers/10.4103/2230-8210.163171
- The paper
- Kalra, S., Aamir, A., Raza, A., Das, A., Azad Khan, A., Shrestha, D., Qureshi, M. F., Fariduddin, M., Pathan, M. F., Jawad, F., Bhattarai, J., Tandon, N., Somasundaram, N., Katulanda, P., Sahay, R., Dhungel, S., Bajaj, S., Chowdhury, S., Ghosh, S., . . . Bulughapitiya, U. (2015). Place of sulfonylureas in the management of type 2 diabetes mellitus in South Asia: A consensus statement. Indian Journal of Endocrinology and Metabolism. https://doi.org/10.4103/2230-8210.163171
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.